Side-by-side · Research reference
BPC-157vsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed9/53 cited
BPhase 2Reviewed8/46 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
BPC-157
TB-500
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014Sikiric 2018
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Endogenous protein at baseline; supplementation amplifies
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
TB-500
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
2× per week (loading); then 1× per week (maintenance)
Lower / starter dose
200 mcg / day
Conservative starter for new users.
1 mg per injection
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
4–8 weeks loading; longer maintenance for chronic injury
Reconstitution
Bacteriostatic water, 1–2 mL
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
Evening or pre-rest preferred (anecdotal)
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~2 hours (estimated; tissue uptake longer)
04Side Effects & Safety
Parameter
BPC-157
TB-500
Injection site reaction
Mild irritation (anecdotal)
Mild erythema, transient pain
GI symptoms
None reported in PL-14736 Phase 2
Rare nausea (anecdotal)
Cardiovascular
Not reported
—
Cancer risk
Theoretical concern via VEGF angiogenesis pathwaySikiric 2018
Theoretical via angiogenesis pathway
Antibody formation
No data (no long-term human trials)
No data (no long-term human trials)
Pregnancy / OB
Avoid — insufficient safety data
Avoid
Long-term safety
Unknown beyond Phase 2 trial duration
Unknown beyond Phase 2
Drug interactions
None established
—
Lethargy / fatigue
—
Reported anecdotally during loading phase
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
BPC-157
TB-500
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Evening or pre-sleep is most common anecdotal timing.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair